Studio di sicurezza e tollerabilità di ST-503 per dolore refrattario associato alla neuropatia a fibra piccola
Uno studio di escalation della dose in doppio cieco, randomizzato, randomizzato, randomizzato, randomizzato per determinare la sicurezza e la tollerabilità della terapia genica ST-503 intratecale a dose singola per il dolore refrattario a causa della neuropatia idiopatica a fibra ridotta (ISFN)
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).
ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).
Small fiber neuropathy happens when something damages small nerve fibers in your skin, causing symptoms like painful tingling or burning sensations in your hands and feet. Pain originating in the nerves outside of the brain and spinal cord is defined by doctors as neuropathic pain. Scientists have discovered that certain proteins in our bodies called sodium channels are important for communicating pain signals in nerves, specifically, Nav1.7, Nav1.8 and Nav1.9. This first-in-human study will test the use of a type of experimental treatment called "gene therapy." The primary goal is to determine if it is safe and well tolerated. The second goal is to determine if it reduces the level of refractory pain due to SFN disease. The gene will be delivered into your cells using a special delivery tool called a vector.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Arizona
-
Scottsdale, Arizona, Stati Uniti, 85260
- HonorHealth
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
La Jolla, California, Stati Uniti, 92093
- The University of California, San Diego
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21218
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital
-
-
New Hampshire
-
Lebanon, New Hampshire, Stati Uniti, 03766
- Dartmouth Hitchcock Medical Center
-
-
New York
-
New York, New York, Stati Uniti, 10027
- Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH)
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- University of North Carolina Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37235
- Vanderbilt University
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- University of Utah
-
-
Virginia
-
Richmond, Virginia, Stati Uniti, 23284
- Virginia Commonwealth University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria
- Diagnostic characterization of Small Fiber Neuropathy (SFN) according to the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) criteria.
- Medical record documentation that pain is refractory to 2 of 3 categories of first line medical therapy for at ≥ 6 months prior to screening.
- Serum sample negative for pre-existing anti-AAV9 antibodies determined by assay detection limit
Exclusion Criteria
-
Drug- and alcohol-related:
- Persons using opioid analgesics for under 3 months or persons who are not on a stable dose of opioids; if on a stable dose, the dose may decrease over the course of the study but should not be increased.
- History of known alcohol abuse, opioid analgesic abuse, or illicit drug abuse within 2 years of Screening.
- Positive urine test for drugs of abuse (including opiates, benzodiazepines, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription and investigator approval, at Screening and Day -1.
- Use of cannabinoids is not permitted.
-
Persons with Fabry's disease, with erythromelalgia, with peripheral neuropathies due to alcohol or drug toxicity, or with diagnosed channelopathies
-
Procedure-related:
- Contraindications to LP, general anesthesia or sedation
- Any medical disorders that, in the opinion of the Investigator, could interfere with LP including but not limited to evidence for a pressure gradient between supratentorial and infratentorial compartments, Arnold-Chiari malformation, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, increased intracranial pressure, or spine disease or past surgical procedures involving the spine
-
Infectious disease-related:
- Active viral infection or bacterial
- A severe infection (e.g., pneumonia, septicemia, central nervous system infections [e.g., meningitis, encephalitis]) within 12 weeks prior to Screening
-
Hepatic disease- and hepatotoxic medication-related:
- Presence of clinically relevant liver disease
- Hepatic dysfunction as indicated by one or more of the following: i. Albumin ≤ 3.5 g/dL ii. Total bilirubin > 1.5 x ULN and direct bilirubin ≥0.5 mg/dL iii. Alkaline phosphatase (ALP) > 2 x ULN iv. Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 x ULN
- Hepatotoxic medications should be avoided during the study period including acetaminophen exceeding 4 gm/day unless essential to patient's treatment, approved by investigator, and hepatic dysfunction is not identified
- Hepatotoxic supplement use during the study period
-
Cancer-related:
a. History of cancer, including B-cell cancers, within 5 years of Screening
i. Exceptions to this exclusion are fully excised non-melanoma skin cancers, non-metastatic prostate cancer, and fully treated ductal carcinoma in situ of the breast, provided subject has been stable for at least 6 months
b. Previous autologous or allogeneic bone marrow transplant, peripheral stem cell transplant or solid organ transplantation
-
Previously received gene or cellular therapy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore fittizio: Studio controllato sham
|
Sham Procedure |
|
Sperimentale: Agente investigativo
|
Genomic Medicine |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence and severity of treatment emergent adverse events (TEAEs)
Lasso di tempo: 12 weeks
|
To assess safety and tolerability of ST-503 over a 12-week post-dosing observation period. |
12 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of subjects with pain intensity reduction from baseline at Week 12
Lasso di tempo: 12 weeks
|
|
12 weeks
|
|
Percentage of subjects at Week 12
Lasso di tempo: 12 weeks
|
|
12 weeks
|
|
Columbia Suicide Severity Rating Scale (CSSRS) Rating
Lasso di tempo: 12 weeks
|
With a ≥ 1-point decline in suicidal ideation in Columbia Suicide Severity Rating Scale (CSSRS) responses |
12 weeks
|
|
Overall Pain Intensity Numerical Rating Scale (PI-NRS) score
Lasso di tempo: 12 Weeks
|
Participants will rate their pain intensity using an 11-point Numerical Rating Scale (0=no pain and 10=worst possible pain) and record their score in an electronic diary. |
12 Weeks
|
|
Short Form McGill Pain Questionnaire-2 (SF-MQ-2)
Lasso di tempo: 12 Weeks
|
This pain scale was developed to evaluate chronic neuropathic and non-neuropathic pain in adults. It consists of 22 descriptors of pain in 4 parts (continuous, intermittent, neuropathic, and affective pain types) to be rated from 0-10 with 0 indicating no pain and 10 the worst pain ever during the past week. |
12 Weeks
|
|
Daily Sleep Interference Score (DSIS)
Lasso di tempo: 12 Weeks
|
DSIS is assessed on an 11-point NRS, which ranges from 0 (none) to 10 (severe). |
12 Weeks
|
|
Hospital Anxiety and Depression Scale (HADS)
Lasso di tempo: 12 Weeks
|
HADS is a screening tool for anxiety and depression in non-psychiatric clinical populations consisting of 14 items (seven each for anxiety and depression). Higher scores correlate with worse symptoms. |
12 Weeks
|
|
Rasch-Transformed 13-item SFN Symptoms Inventory Questionnaire
Lasso di tempo: 12 Weeks
|
The 13-item SFN-SIQ evaluates changes in physiological functions such as sweating patterns and incontinence using a four-point Likert scale (0 = never present, 1 = sometimes, 2 = often, and 3 = always present) to get a sum of the grading scores attributed to each of the 13 items with a 0 to 39 range. Higher scores correlate with worse symptoms. |
12 Weeks
|
|
SFN-specific Rasch-built Overall Disability Scale (SFN-RODS)
Lasso di tempo: 12 Weeks
|
The 32-item SFN-RODS is a disease-specific interval measure suitable to detect activity limitations and participation restrictions in patients with SFN. The scale ranges from 0 to 64 with higher numbers indicating worse disability. |
12 Weeks
|
|
36-Item Short Form Health Survey (SF-36) domains and summary scores
Lasso di tempo: 12 Weeks
|
This measures quality of life measures such as physical functioning, emotional well-being, energy levels, and social functioning. The range is from 0-100 with higher scores being associated with a better perceived quality of life. |
12 Weeks
|
|
Pain Catastrophizing Questionnaire (PCS)
Lasso di tempo: 12 Weeks
|
PCS has 13 questions related to rumination, magnification and helplessness with values ranging 0 to 4 for a total possible score of 52. The higher the score the more pain catastrophizing is present. |
12 Weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Medical Monitor, Sangamo Therapeutics Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ST-503-101
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .